SEC31A
Biomarker
SEC31A participates in intracellular protein transport. Alterations have been explored in emerging biomarker research.
Approvals
1
Indications
1
Therapies
2
Mapped tests
1
Where this biomarker is used
Each approval combines this biomarker with a specific indication and therapy. Select a therapy in the tables below to open its FDA-defined testing pathway.
Indication-specific approvals
Approvals where SEC31A is defined directly in the indication labeling.
| Indication | Biomarker criteria | Therapies |
|---|---|---|
Colorectal Cancer (CRC) Solid Tumor · Colorectal |
|
Tumor-agnostic approvals
Approvals defined at the solid tumor level where SEC31A is part of the eligibility criteria.
No tumor-agnostic approvals are currently mapped for this biomarker.
Tests that measure this biomarker
These assays report SEC31A as part of their validated menu. In many cases they are identified in FDA labeling as acceptable companion diagnostics for specific approvals.
Test
Idylla CDx MSI Test
Biocartis US Inc.
Method
PCR
Specimen
Tissue (FFPE)
Reports SEC31A as part of its biomarker panel.
1 approvalView test profile →